S0820, Adenoma and Second Primary Prevention Trial
a study on Colorectal Cancer Colorectal Tumor Rectal Cancer
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Costa Mesa, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Jason A. Zell, D.O., MPH
Description
Summary
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.
Official Title
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Details
The purpose of this study is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg (compared to corresponding placebos) has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas >/= 0.3 cm, total advanced colorectal events, or total colorectal events.
Keywords
Colorectal Neoplasms, Eflornithine/sulindac prevention trial, Adenoma, Eflornithine, Sulindac, Eflornithine plus sulindac
Eligibility
You can join if…
Open to people ages 18 years and up
- History of Stage 0-III colon or rectal cancer with primary resection 1 year previously
- Post-operative colonoscopy and CT scans of chest, abdomen & pelvis showing no evidence of disease
- Must not have cardiovascular risk factors including unstable angina, history of myocardial infarction, or cerebrovascular accident, coronary artery bypass surgery, or NY Heart Assoc Class III or IV heart failure.
- Patients must not have known uncontrolled hyperlipidemia (defined as LDL-C >/= 190 mg/dL or triglycerides >/= 500 mg/dL within the past 3 years or uncontrolled high blood pressure (systolic blood pressure > 150 mm Hg) within 28 days prior to registration
- At least 30 days from completion of adjuvant chemo and RT.
- Presence of gastroesophageal reflux disease acceptable if controlled with medications
- Not receiving or planning to receive concomitant intravenous corticosteroids on a regular basis,nonsteroidal anti-inflammatory drugs (NSAIDs), nor anticoagulants on a regular predictable intermittent basis. NSAID use must not exceed 10 days per month; Maximum aspirin dose
- 100 mg per day or ≤ two 325 mg tablets per week. Inhaled steroids (i.e. for asthma or related conditions) are allowed.
- Able to swallow oral medications
- Laboratory: WBC ≥ 4.0 x 1000/mcL, platelets ≥ 100,000/mcL and hemoglobin > 11.0 g/dL. (A total WBC ≥ 3.1 x 1000/mcL is allowed for non-Hispanic black males and total WBC ≥ 3.4 x 1000/mcL for non-Hispanic black females. Serum bilirubin ≤ 2.0 mg/dL and AST (SGOT) or ALT(SGPT) ≤ 2 x IULN. Serum creatinine ≤ 1.5 x IULN
- Zubrod PS 0-1, 18 years of age or older
- Will not participate in any other clinical trial for the treatment or prevention of cancer unless off protocol treatment, on follow-up phase only
- Offered opportunity to participate in blood specimen banking
You CAN'T join if...
- History of colon resection > 40 cm
- Mid-low rectal cancer
- Recurrent or metastatic disease
- High cardiovascular risk; Uncontrolled hypertension
- Planned radiation therapy or additional chemotherapy
- Documented history of gastric/duodenal ulcer within last 12 months and/or current treatment or active symptoms of gastric/duodenal ulcer
- Known history of familial adenomatous polyposis, hereditary nonpolyposis colorectal cancer, or inflammatory bowel disease
- ≥ 30 dB uncorrectable hearing loss for age of any of the five tested frequencies on prestudy audiogram
- Known hypersensitivity to sulindac or excipient byproducts. Previous asthma, urticaria, or allergic-type reaction to aspirin or other NSAIDs
- Significant medical or psychiatric condition that would preclude study completion (8 years)
- No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free for > 5 years
- Pregnant or nursing women. Women/men of reproductive potential must agree to use effective contraception
Locations
- UC Irvine Health Cancer Center-Newport
accepting new patients
Costa Mesa California 92627 United States - UCI Health Laguna Hills
accepting new patients
Laguna Hills California 92653 United States - UC Irvine Health/Chao Family Comprehensive Cancer Center
accepting new patients
Orange California 92868 United States - Kaiser Permanente-Irvine
accepting new patients
Irvine California 92618 United States - Saint Joseph Hospital - Orange
currently not accepting new patients, but might later
Orange California 92868 United States - Kaiser Permanente-Anaheim
accepting new patients
Anaheim California 92806 United States - Kaiser Permanente-Bellflower
accepting new patients
Bellflower California 90706 United States - Presbyterian Intercommunity Hospital
currently not accepting new patients, but might later
Whittier California 90602 United States - Kaiser Permanente - Harbor City
accepting new patients
Harbor City California 90710 United States - Kaiser Permanente-Riverside
accepting new patients
Riverside California 92505 United States
Lead Scientist at UC Irvine
- Jason A. Zell, D.O., MPH
Professor, Medicine, School of Medicine. Authored (or co-authored) 91 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- SWOG Cancer Research Network
- ID
- NCT01349881
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 1340 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.